Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder (HOTPIN-IF)

13 de maio de 2026 atualizado por: University of Colorado, Denver

Facilitating In-Hospital Opioid Treatment Program Intakes to Support Hospital to OTP Linkage Among Hospitalized Patients With Opioid Use Disorder: An Implementation Trial in Four Hospitals

The goal of this clinical trial is to learn if a hospital-based approach can help people with opioid use disorder (OUD) connect to a methadone clinic after leaving the hospital. This study focuses on adults with OUD who are in the hospital and want to start methadone treatment. Methadone is a safe and effective treatment for OUD. It can reduce cravings, prevent withdrawal, and lower the risk of overdose and death. Even though methadone works well, many people do not receive it. For people who start treatment in the hospital, the time after discharge is a high-risk period. Many patients do not connect to a methadone clinic after they leave. This can lead to return to opioid use, overdose, repeat hospital visits, and poor health. This study tests a new approach where hospital teams help complete the methadone clinic intake during the hospital stay. This approach uses trained hospital staff and structured workflows to complete key parts of the intake process before discharge. The goal is to reduce delays and make it easier for patients to connect to care right after leaving the hospital. The main questions it aims to answer are: 1) Does completing a methadone clinic intake during the hospital stay increase the number of people who connect to a methadone clinic after discharge? 2) Does providing support to hospital teams increase how often these in-hospital intakes are completed? Researchers will compare usual hospital care (referral at discharge) to a hospital-based approach that helps complete methadone clinic intake during the hospital stay to see if this improves connection to care.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

The purpose of this study is to test whether a hospital-based approach can improve connection to methadone treatment after discharge. The approach includes completing OTP intake during hospitalization and supporting hospital teams through an implementation strategy called implementation facilitation (IF). This study also aims to understand how well the approach can be adopted and sustained across different hospitals. This is a multi-site clinical trial conducted at four hospitals. The study uses a hybrid type 2 implementation-effectiveness design, meaning it evaluates both patient outcomes and how the intervention is implemented. The study uses an incomplete stepped wedge cluster randomized design. In this design:

  • All hospitals begin in a usual care phase
  • Hospitals are randomly assigned a time to switch to the intervention
  • Over time, each hospital transitions from usual care to the intervention phase
  • This allows each hospital to serve as its own comparison

During the usual care phase, patients receive standard care, which includes referral to an OTP at discharge. During the intervention phase, hospital teams receive implementation support to help complete OTP intake during the hospital stay. The intervention is an implementation strategy designed to support hospital teams in completing OTP intake during hospitalization.

The study uses the RE-AIM framework to evaluate outcomes:

  • Reach: The number and characteristics of patients who complete OTP intake and connect to care.
  • Effectiveness: The primary outcome is connection to an OTP after hospital discharge (for example, within 7 days). Secondary outcomes may include engagement in treatment at 30 and 90 days, healthcare use, and mortality.
  • Adoption: The proportion of hospital clinicians and teams who use the new workflows and complete OTP intake.
  • Implementation: How well the intervention is delivered, including fidelity to core components, adaptations, and resources used.
  • Maintenance: Whether the intervention is sustained over time after initial implementation.

The study will also assess implementation costs and identify barriers and facilitators to adoption.

Participants are adults with OUD who are hospitalized and interested in starting methadone treatment. Participants must be willing to connect to a methadone clinic after discharge.

Data will be collected from multiple sources, including:

  • Electronic health records (EHRs) from participating hospitals
  • Data from opioid treatment programs (when available)
  • Study questionnaires completed during enrollment
  • Administrative data on healthcare use
  • National Death Index data for mortality outcomes
  • Data will be combined across sites using a structured data approach to ensure consistency.

The analysis will evaluate:

  • Differences in OTP connection rates
  • Changes in treatment engagement over time
  • Variation across hospitals
  • Implementation outcomes and costs
  • Qualitative data from interviews and observations may also be used to understand how the intervention works in real-world settings.

This study addresses a major gap in care for people with OUD. Improving connection to methadone treatment after hospitalization has the potential to reduce overdose deaths, improve health outcomes, and reduce healthcare use. By testing both effectiveness and implementation, this study will provide practical information for scaling this approach across hospitals.

If successful, this model could be widely adopted to improve access to life-saving treatment for people with OUD.

Tipo de estudo

Intervencional

Inscrição (Estimado)

1440

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Age ≥18 years
  • Hospitalized with DSM-5 opioid use disorder, confirmed by clinical assessment
  • Eligible for methadone treatment as determined by the clinical team
  • Not currently enrolled in an Opioid Treatment Program (OTP)
  • Anticipated discharge to the community
  • Willing to initiate methadone and follow up at a partnering OTP

Exclusion Criteria:

  • Current enrollment in an Opioid Treatment Program (OTP)
  • Planned discharge to a correctional or institutional setting that precludes OTP follow-up
  • Medical or psychiatric instability that precludes safe methadone initiation or completion of study procedures
  • Inability to provide required information for OTP intake due to impaired cognition or altered mental status

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: N / D
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Usual Care
Standard hospital-to-OTP referral processes without implementation facilitation

Participants receive care at sites after rollout of Implementation Facilitation (IF) to support HOTPIN workflows.

Focus on completing in-hospital OTP intake, including:

Medical assessment Screening labs Methadone initiation Transportation coordination

Supported by:

External facilitators Learning collaboratives Workflow integration into the EHR

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
7-Day Hospital-to-OTP Linkage
Prazo: Measured within 7 days following hospital discharge

The primary outcome is whether a participant successfully connects to an Opioid Treatment Program (OTP) within 7 days after hospital discharge. Connection" (linkage) is defined as:

Completion of OTP intake and/or attendance at the OTP, and Receipt or continuation of methadone treatment at the OTP

Measured within 7 days following hospital discharge

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
30-Day OTP Engagement
Prazo: 30 days after hospital discharge

Description:

Proportion of participants who remain engaged in methadone treatment at an Opioid Treatment Program (OTP) within 30 days after hospital discharge.

Defined by ongoing dosing or documented attendance at the OTP Reflects short-term treatment retention

30 days after hospital discharge
90-Day OTP Engagement (Retention)
Prazo: Within 90 days after hospital discharge

Description:

Proportion of participants who remain engaged in methadone treatment at an OTP within 90 days after hospital discharge.

Defined by continued dosing records or clinic attendance Reflects longer-term treatment retention

Within 90 days after hospital discharge

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Healthcare Utilization After Discharge
Prazo: 90 days following hospital discharge

Description:

Rates of emergency department visits and hospital readmissions following the index hospitalization.

Assessed using hospital administrative and EHR data

90 days following hospital discharge
All-cause mortality following hospital discharge.
Prazo: 90 days after hospital disharge
Assessed using linkage to the National Death Index (NDI)
90 days after hospital disharge

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Susan L Calcaterra, MD, MPH, MS, University of Colorado, Denver

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de outubro de 2026

Conclusão Primária (Estimado)

31 de outubro de 2030

Conclusão do estudo (Estimado)

30 de novembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

24 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de abril de 2026

Primeira postagem (Real)

6 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

We will share de-identified individual participant data (IPD) using a controlled access process (not open download)

We will require:

Data Use Agreement (DUA) IRB approval or exemption data security plan

We will exclude:

Direct identifiers Anything restricted under 42 CFR Part 2 without proper authorization

Prazo de Compartilhamento de IPD

Time Frame:

Data will be available beginning 12 months after publication of the primary results and ending 5 years after publication.

Critérios de acesso de compartilhamento IPD

Data will be shared with investigators who provide a methodologically sound proposal. Access will require execution of a Data Use Agreement (DUA), Institutional Review Board (IRB) approval or exemption, and adherence to data security requirements.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • ANALYTIC_CODE
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever